腹腔热灌注化疗联合细胞减灭术与单纯细胞减灭术治疗胃癌腹膜转移的对比
HIPEC with CRS versus cytoreductive surgery (CRS) for the gastric cancer metastasis to peritoneum.
作者信息
Chen Zhuming, Ali Muhammad, Kai Zhe, Wang Yang, Wang Chaohui
机构信息
Department of General Surgery, Anqing First People's Hospital of Anhui Medical University, Hefei, China.
Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, 225001, China.
出版信息
Clin Transl Oncol. 2023 Apr;25(4):1011-1016. doi: 10.1007/s12094-022-03004-5. Epub 2022 Nov 18.
BACKGROUND
Peritoneal metastases (PM) have a poor prognosis in gastric cancer (GC). Cytoreductive surgery (CRS) gives favorable outcomes, but the influence of hyperthermic intraperitoneal chemotherapy (HIPEC) remains contentious. We designed to distinguish results between CRS versus HIPEC-CRS in patients with peritoneal metastases from gastric cancer.
MATERIALS AND METHODS
PubMed, Scopus, Embase and Cochrane library accessed to collect data and language is restricted to English. RevMan 5.4 was used to perform statistical analysis. The outcomes for categorical variables are mentioned in the risk ratio.
RESULTS
Ten trials involving 1367 patients in which 707 were CRS-HIPEC, while 660 CRS. We got significant results in 3rd year survival (P < 0.05), while 1st and 5th years are not statistically significant P > 0.05.
CONCLUSION
To compare with CRS, CRS-HIPEC has improved survival rate in deprived of further morbidity or mortality.
背景
腹膜转移（PM）在胃癌（GC）中预后较差。细胞减灭术（CRS）能带来良好的结果，但热灌注腹腔化疗（HIPEC）的影响仍存在争议。我们旨在区分胃癌腹膜转移患者接受CRS与HIPEC - CRS的结果。
材料与方法
通过访问PubMed、Scopus、Embase和Cochrane图书馆收集数据，语言限制为英语。使用RevMan 5.4进行统计分析。分类变量的结果以风险比表示。
结果
10项试验共纳入1367例患者，其中707例行CRS - HIPEC，660例行CRS。我们在第3年生存率方面得到了显著结果（P < 0.05），而第1年和第5年无统计学意义（P > 0.05）。
结论
与CRS相比，CRS - HIPEC提高了生存率，且未增加额外的发病率或死亡率。
Zotero 插件